Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.57 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 8/20 | 0.52 |
| ▸ | SMOX | Q9NWM0 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18353767 | 0.88 | GAA (0.58) | GAAKDM1AHSD17B10RCOR1MAOA | |
| SCHEMBL16995654 | 0.84 | KDM1A (0.50) | GAAKDM1AHSD17B10RCOR1SMOX | |
| SCHEMBL16995687 | 0.76 | KDM1A (0.50) | GAAKDM1AHSD17B10RCOR1MAOA | |
| SCHEMBL16995659 | 0.74 | MAOA (0.54) | GAAKDM1AHSD17B10RCOR1MAOA | |
| SCHEMBL29904208 | 0.73 | GAA (1.00) | GAAKDM1AHSD17B10RCOR1MAOA | |
| SCHEMBL16995707 | 0.73 | GAA (1.00) | GAAKDM1AHSD17B10RCOR1MAOA | |
| SCHEMBL18353484 | 0.72 | KDM1A (0.46) | GAAKDM1AHSD17B10RCOR1SMOX | |
| SCHEMBL16995655 | 0.70 | KDM1A (0.50) | GAAKDM1AHSD17B10RCOR1SMOX | |
| SCHEMBL16995649 | 0.67 | KDM1A (0.72) | GAAKDM1AHSD17B10RCOR1MAOA | |
| SCHEMBL25204041 | 0.67 | SMN1; SMN2 (0.59) | HSD17B10KDM4EPOLBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001968-A1 | AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001968-A1 | AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2015120281-A1 | AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001968-A1 | AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS | KDM1A, KDM1B, KDM3A | GAA 3448/4885KDM1A 1/4885HSD17B10 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.